<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632862</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP16001301</org_study_id>
    <nct_id>NCT04632862</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.</brief_title>
  <official_title>A Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of DWP16001 compared to&#xD;
      placebo in the treatment of type 2 diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c level at Week 24 after administration of the IP</measure>
    <time_frame>at Week 24</time_frame>
    <description>1.Change from Visit 2 (randomization) in HbA1c level at Week 24 after administration of the IP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c level at Weeks 6, 12, and 18 after administration of the IP</measure>
    <time_frame>at weeks 6, 12, and 18</time_frame>
    <description>1.Changes from Visit 2 (randomization) in HbA1c level at Weeks 6, 12, and 18 after administration of the IP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG level at Weeks 6, 12, 18, and 24 after administration of the IP</measure>
    <time_frame>at weeks 6, 12, 18, and 24</time_frame>
    <description>2.Changes from Visit 2 (randomization) in FPG level at Weeks 6, 12, 18, and 24 after administration of the IP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level &lt; 7% at Weeks 6, 12, 18, and 24 after administration of the IP</measure>
    <time_frame>at weeks 6, 12, 18, and 24</time_frame>
    <description>3.Proportions of subjects who achieved HbA1c level &lt; 7% at Weeks 6, 12, 18, and 24 after administration of the IP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>T2DM (Type 2 Diabetes Mellitus)</condition>
  <arm_group>
    <arm_group_label>DWP16001 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Amg, Tablets, Orally, Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP16001 Amg Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DWP16001 Amg Placebo, Tablets, Orally, Once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP16001</intervention_name>
    <description>DWP16001 A mg</description>
    <arm_group_label>DWP16001 Amg</arm_group_label>
    <arm_group_label>DWP16001 Amg Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 19 to 80 years&#xD;
&#xD;
          2. Subjects with 7% ≤ HbA1c ≤ 10% who have been diagnosed with T2DM at least 8 weeks&#xD;
&#xD;
          3. Subjects with BMI of 20-45 kg/m2&#xD;
&#xD;
          4. Subjects who have been on a stable diet and exercise program for at least 8 weeks&#xD;
&#xD;
          5. Subjects who voluntarily decided to participate and provided written consent after&#xD;
             being told of the objectives, method, and effects of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Different type of diabetes mellitus which is not T2DM (type 1 diabetes mellitus,&#xD;
             secondary diabetes mellitus, or congenital renal glucosuria)&#xD;
&#xD;
          2. Symptoms of stress urinary incontinence, dysuria that is not controlled by medications&#xD;
             due to neurogenic bladder or prostatic hyperplasia, anuria, oliguria, or urinary&#xD;
             retention&#xD;
&#xD;
          3. Severe diabetes complications (proliferative diabetic retinopathy, nephropathy of&#xD;
             stage 4 or higher, or serious diabetic neuropathy)&#xD;
&#xD;
          4. eGFR &lt; 60 mL/min/1.73 m2&#xD;
&#xD;
          5. Severe gastrointestinal diseases: active ulcer, gastrointestinal or rectal bleeding,&#xD;
             active inflammatory bowel syndrome, biliary duct obstruction, active gastritis that is&#xD;
             not controlled by medication, etc.&#xD;
&#xD;
          6. Uncontrolled hypertension (SBP &gt;180 mmHg or DBP &gt; 110 mmHg)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Daewoong pharmatceutical</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

